Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 7, 2024
Discovery & Translation
Science spotlight: Roche’s anti-TIGIT mAb benefits from Fc-driven effects and more
BioCentury’s roundup of translational innovations
BioCentury | Jan 27, 2024
Data Byte
EMA’s CHMP confirms non-renewal of Translarna, denies new medicines Nezglyal and Syfovre
On the positive side of the ledger, BMS’s CAR T therapy Abecma headed for a line extension
BioCentury | Dec 3, 2021
Distillery Therapeutics
CpG and aluminum hydroxide adjuvant for COVID-19 protein vaccines
BioCentury | Jul 2, 2021
Distillery Therapeutics
A CD81-targeting mAb for solid tumors
DISEASE CATEGORY: Cancer
INDICATION: Breast cancer; lung cancer A mAb targeting the tetraspanin CD81 could treat breast and lung cancers. In human triple-negative breast cancer (TNBC) and lung
INDICATION: Breast cancer; lung cancer A mAb targeting the tetraspanin CD81 could treat breast and lung cancers. In human triple-negative breast cancer (TNBC) and lung
BioCentury | Jul 28, 2016
Targets & Mechanisms
Effectorless efficacy
How Genentech is making mAbs safer for CNS diseases
Items per page:
1 - 10 of 24